• TG Therapeutics plans to present new clinical data for BRIUMVI at the upcoming ACTRIMS annual forum.
• The updates will cover Phase 4 real world infusion experience, pediatric trial designs, and biomarker findings in relapsing multiple sclerosis.
• The breadth of data is aimed at further defining BRIUMVI's clinical profile beyond previously shared information.

TG Therapeutics, trading on NasdaqCM:TGTX, is drawing fresh attention with this planned data package around BRIUMVI. The stock last closed at $30.68, with a 3 year return of 111.6% alongside a 5 year return of a 36.7% decline, which highlights the volatility shareholders have experienced. For investors following the multiple sclerosis space, these upcoming readouts provide additional context on how the company is working to build out its commercial and clinical story.

The real world, pediatric, and biomarker data sets may help investors better understand how BRIUMVI might fit across different patient groups and treatment decisions. As those results are presented and discussed at ACTRIMS, attention is likely to focus on how they compare with existing options and whether they address practical questions around use in day to day practice.

Stay updated on the most important news stories for TG Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on TG Therapeutics.

Quick Assessment

• ✅ Price vs Analyst Target: At US$30.68, the price sits below the US$44.86 analyst target range midpoint.
• ✅ Simply Wall St Valuation: Shares are flagged as undervalued, trading around 76.7% below an estimated fair value.
• ❌ Recent Momentum: The 30 day return is roughly a 0.3% decline.

Check out Simply Wall St's in depth valuation analysis for TG Therapeutics.

Key Considerations

• 📊 The ACTRIMS data on real world use, pediatrics, and biomarkers could influence how durable BRIUMVI's revenue story appears to the market.
• 📊 Watch investor reaction to safety and infusion experience details, as well as any indications of how BRIUMVI compares with other multiple sclerosis treatments.
• ⚠️ One flagged risk is a high level of non cash earnings, so you may want to separate cash generation from accounting items when reviewing results.

Dig Deeper

For the full picture including more risks and rewards, check out the complete TG Therapeutics analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.